Tectonic Therapeutic opened lower at $21.75, compared with its previous close of $21.96. In the last trading session, the stock traded between $20.20 and $21.75. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Tectonic Therapeutic is now worth
$ 123.82
Giving a profit of
$ 23.82 (23.82%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
83.33%
Hold
16.67%
Sell
0%
Markets Today
Today's Change
$-0.90 (-4.09%)
Day High
$21.75
Day Low
$20.20
Day Open
$21.75
Prev Close
$21.96
Volume
1,02,376
1W Return
3.85%
1M Return
-5.97%
3M Return
-33.97%
6M Return
-23.47%
1Y Return
10.97%
Fundamentals
Market Cap ($ Mn)
420
PE Ratio
-
PB Ratio
3.05
PEG Ratio
-
ROE
-29.79%
ROCE
-33.78%
EPS (TTM)
-
Investment Returns
1 Week
3.85%
1 Month
-5.97%
3 Months
-33.97%
6 Months
-23.47%
9 Months
-4.31%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
12Oct
UBS initiates Tectonic Therapeutic coverage with Neutral rating, $26 target
UBS initiates coverage on Tectonic Therapeutic with a Neutral rating. Analyst Alice Nettleton sets a price target of $26 per share.
Tectonic Therapeutics delivered a second-quarter EPS of $(1.18), surpassing the $(1.37) consensus estimate by 13.87%. Despite the beat, losses expanded by 10.28% compared to the prior year's $(1.07) per share, reflecting continued operational challenges amidst improved-than-expected cost containment.
3mo ago
11Jun
Tectonic completes enrollment in TX45 APEX Phase 2 trial
Tectonic Therapeutic has completed enrollment in its APEX Phase 2 trial for TX45, targeting PH-HFpEF patients. The study enrolled 191 patients globally, with a focus on the severe CpcPH subgroup. Topline results are anticipated in early Q1 2027.
